Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a shot replace daily blood pressure pills?

NCT ID NCT07835971

Disease control Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 23, 2026 · Last updated Sep 24, 2026 · Updated 1 time

Summary

Researchers are testing GW906, an experimental injectable drug, in adults with essential hypertension. The Phase II trial compares GW906 with a placebo injection in about 319 people aged 18 to 75 whose systolic blood pressure is between 140 and 180 mmHg. The main goal is to see how much the drug lowers sitting systolic blood pressure after 12 weeks, with additional checks at 4, 8, and 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GW906 (SAL0132), an experimental injectable drug
What this could lead to
If it works, GW906 could offer a new injectable option for lowering blood pressure in people whose hypertension is not well controlled.
What could go wrong
This is a Phase II trial, so researchers still need to confirm whether the drug works and whether it is safe. Injections can cause reactions, and blood pressure drugs sometimes fail to show benefit or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

319 people

The number who actually took part.

Started

Dec 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years and ≤ 75 years, of either sex. * Mean sitting systolic blood pressure (msSBP) ≥ 140 mmHg and \< 180 mmHg at screening. * Willing to participate in the study and provide written informed consent. Exclusion Criteria: * Secondary hypertension. * orthostatic hypotension. * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5× upper limit of normal (ULN); Total bilirubin \> 1.5 × ULN; International normalized ratio (INR) \> 2.0; Serum potassium \> 5.0 mmol/L or \< 3.5 mmol/L; eGFR≤30 mL/min/1.73m\^2. * Received an investigational agent within the last 3 months. * Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus. * History of any cardiovascular event within 12 months. * History of intolerance to SC injection(s).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential hypertension are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

Contacts and locations

Locations

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China

    Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.